Understand · Discuss · Plan together

Genetic Testing in Cancer Patients vs Healthy Relatives

Testing can inform cancer treatment, future prevention and family care—but these are separate decisions.

Chapter 10 of 16

10 of 16
Explore all 16 chapters

For someone with cancer

A germline result may affect treatment eligibility in selected settings and help assess second-cancer risks. A somatic tumour panel may identify treatment targets without establishing hereditary risk. Ask the oncologist which type of test is being ordered, why it matters now and whether confirmation is required. Do not delay essential treatment while arranging family testing unless the treating team recommends it.

For a healthy relative

The main goal is future risk management. If a pathogenic familial variant is documented, a targeted test can answer whether that relative inherited it. Screening decisions should account for age, organs present and other risks. A relative may need earlier assessment because of family history even before a molecular cause is found.

Cascade testing

With the tested person’s permission, provide relatives with a copy of the relevant report or a genetics-service family letter. Each relative should receive their own counselling and consent process. Do not assume every relative needs the same broad panel. The pattern of who should be offered testing differs for dominant and recessive conditions.

When the affected relative cannot be tested

Ask whether records or stored material exist and whether their use is appropriate and permitted. An unaffected relative can still be assessed. Discuss that a negative test may be less informative in this situation, and agree a plan based on the remaining evidence.

Special sample situations

Tell the genetics team about a blood cancer or an allogeneic stem-cell transplant. Blood or saliva may not always be the right sample for determining constitutional DNA in these circumstances; specialist laboratory advice may be needed.

Sources and further reading

Accessible sources checked: 19 October 2026. International recommendations are identified where used; care in India requires individual clinical assessment. No claim is made to have directly verified restricted NCCN guidance.